Last reviewed · How we verify

Bright Minds Biosciences Pty Ltd — Portfolio Competitive Intelligence Brief

Bright Minds Biosciences Pty Ltd pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 1 shared drug class
  2. Archigen Biotech Limited · 1 shared drug class
  3. AstraZeneca · 1 shared drug class
  4. BioLineRx, Ltd. · 1 shared drug class
  5. Celtic Pharma Development Services · 1 shared drug class
  6. Daewoong Pharmaceutical Co. LTD. · 1 shared drug class
  7. Eric Stephen Winer, MD · 1 shared drug class
  8. Ferrer Internacional S.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Bright Minds Biosciences Pty Ltd:

Cite this brief

Drug Landscape (2026). Bright Minds Biosciences Pty Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bright-minds-biosciences-pty-ltd. Accessed 2026-05-16.

Related